Detection of low-frequency HIV type 1 reverse transcriptase drug resistance mutations by ultradeep sequencing in naive HIV type 1-infected individuals

AIDS Research and Human Retroviruses

Volumn 30, Issue 2, 2014, Pages 170-173

  Bellecave, Pantxika ^a   Recordon Pinson, Patricia ^a   Papuchon, Jennifer ^a   Vandenhende, Marie Anne ^a   Reigadas, Sandrine ^a   Tauzin, Brigitte ^a   Fleury, Hervé ^a  

^a University Victor Segalen   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS RNA; ZIDOVUDINE;

AMPLICON; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; FRANCE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; ULTRADEEP PYROSEQUENCING; UNIVERSITY HOSPITAL; VIRUS LOAD;

DRUG RESISTANCE, VIRAL; FRANCE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION, MISSENSE;

EID: 84893495651     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0130     Document Type: Article

References (17)

1. Palella FJ Jr., Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
2. Hirsch MS, Gunthard HF, Schapiro JM, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47:266-285.
3. Vercauteren J, Wensing AM, van de Vijver DA, et al.: Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis 2009;200:1503-1508.
4. Descamps D, Chaix ML, Montes B, et al.: Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIVinfected patients from 2001 to 2006/2007 in France. J Antimicrob Chemother 2010;65:2620-2627.
5. Larder BA, Kohli A, Kellam P, et al.: Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993;365:671-673.
6. Li JZ, Paredes R, Ribaudo HJ, et al.: Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis. JAMA 2011;305:1327-1335.
7. Bennett DE, Camacho RJ, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drug resistance: 2009 update. PLoS One 2009;4:e4724.
8. Vandenbroucke I, Van Marck H, Verhasselt P, et al.: Minor variant detection in amplicons using 454 massive parallel pyrosequencing: Experiences and considerations for successful applications. Biotechniques 2011;51:167-177.
9. Recordon-Pinson P, Papuchon J, Reigadas S, et al.: K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: Comparison of Sanger and UDP sequencing data. PLoS One 2012;7:e36549.
10. Pingen M, van der Ende M, Wensing A, et al.: Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations. HIV Med 2013;14:176-181.
11. Varghese V, Shahriar R, Rhee SY, et al.: Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: Implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2009;52: 309-315.
12. Nicot F, Saliou A, Raymond S, et al.: Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. J Clin Virol 2012;55:107-113.
13. Deval J, White KL, Miller MD, et al.: Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem 2004;279:509-516.
14. Maïga AI, Descamps D, Morand-Joubert L, et al.: Resistanceassociated mutations to etravirine (TMC-125) in antiretroviralnai 've patients infected with non-B HIV-1 subtypes. Antimicrob Agents Chemother 2010;54(2):728-733.
15. Sharma M and Saravolatz LD: Rilpivirine: A new nonnucleoside reverse transcriptase inhibitor. J Antimicrob Chemother 2013;68(2):250-256.
16. Goodman DD, Zhou Y, Margot NA, et al.: Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 2011;25:325-333.
17. Johnson VA, Calvez V, Günthard HF, et al.: 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011;19:156-164.